Avoid Errors With the New Monoclonal Antibodies for COVID-19

Bamlanivimab and casirivimab/imdevimab will be the first meds authorized to treat OUTPATIENTS with COVID-19.

These new monoclonal antibodies, or "mabs," block the virus that causes COVID-19...SARS-CoV-2...from entering cells.

Both meds are single-dose IV infusions given over 1 hour.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote